Labcorp Holdings Management

Management Kriterienprüfungen 3/4

Labcorp Holdings CEO ist Adam Schechter , ernannt in Nov 2019, hat eine Amtszeit von 11.58 Jahren. Die jährliche Gesamtvergütung beträgt $15.98M , bestehend aus 8.6% Gehalt und 91.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.1% der Aktien des Unternehmens, im Wert von $21.10M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.3 Jahre bzw. 9.7 Jahre.

Wichtige Informationen

Adam Schechter

Geschäftsführender

US$16.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	8.6%
Amtszeit als Geschäftsführer	5yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	4.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Adam Schechter im Vergleich zu den Einnahmen von Labcorp Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$436m
Jun 30 2024	n/a	n/a	US$450m
Mar 31 2024	n/a	n/a	US$399m
Dec 31 2023	US$16m	US$1m	US$379m
Sep 30 2023	n/a	n/a	US$583m
Jun 30 2023	n/a	n/a	US$677m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$15m	US$1m	US$1b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$21m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$3b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$15m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$845m
Jun 30 2020	n/a	n/a	US$362m
Mar 31 2020	n/a	n/a	US$321m
Dec 31 2019	US$6m	US$208k	US$824m
Sep 30 2019	n/a	n/a	US$755m
Jun 30 2019	n/a	n/a	US$853m
Mar 31 2019	n/a	n/a	US$896m
Dec 31 2018	US$301k	n/a	US$884m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$290k	n/a	US$1b

Vergütung im Vergleich zum Markt: AdamDie Gesamtvergütung ($USD15.98M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD5.71M).

Entschädigung vs. Einkommen: AdamDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Adam Schechter (59 yo)

5yrs

Amtszeit

US$15,979,355

Vergütung

Mr. Adam H. Schechter serves as the President, CEO & Chairman of Laboratory Corporation of America Holdings. Mr. Adam serves as President & Chief Executive Officer at Labcorp Holdings Inc. since November...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Adam Schechter	President	5yrs	US$15.98m	0.10% $ 21.1m
Glenn Eisenberg	CFO & Executive VP	10.4yrs	US$4.96m	0.037% $ 7.5m
Mark Schroeder	Executive VP	1.5yrs	US$3.80m	0.0060% $ 1.2m
Brian Caveney	EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer	1.5yrs	US$3.48m	0.033% $ 6.7m
Anita Graham	Executive VP & Chief Human Resources Officer	1.6yrs	US$2.56m	0.00035% $ 70.6k
Peter Wilkinson	Senior VP & Chief Accounting Officer	5.6yrs	keine Daten	0.0025% $ 504.5k
Akinbolade Oyegunwa	Executive VP and Chief Information & Technology Officer	less than a year	keine Daten	0.0032% $ 643.8k
Christin O'Donnell	Vice President of Investor Relations	no data	keine Daten	keine Daten
Sandra van der Vaart	Executive VP	5.8yrs	keine Daten	0.0044% $ 886.0k
Amy Summy	Executive VP & Chief Marketing Officer	4.7yrs	keine Daten	0.0047% $ 958.6k
Marcia Eisenberg	Enterprise Chief Scientific Officer & Senior VP	no data	keine Daten	keine Daten
Deborah Sesok-Pizzini	Chief Medical Officer	3.8yrs	keine Daten	keine Daten

4.3yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: 0JSYDas Führungsteam des Unternehmens gilt als erfahren (4.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Adam Schechter	President	11.6yrs	US$15.98m	0.10% $ 21.1m
Peter Neupert	Independent Director	11.8yrs	US$357.87k	0.014% $ 2.9m
Kerrii Anderson	Independent Director	18.5yrs	US$340.73k	0.017% $ 3.4m
Garheng Kong	Lead Independent Director	10.9yrs	US$375.73k	0.014% $ 2.9m
Richelle Parham	Independent Director	8.8yrs	US$341.44k	0.010% $ 2.1m
D. Gilliland	Independent Director	10.6yrs	US$330.01k	0.010% $ 2.1m
Jeffrey Davis	Independent Director	4.9yrs	US$344.30k	0.0043% $ 873.9k
Paul Rothman	Independent Director	1.4yrs	US$208.42k	0.00087% $ 175.6k
Kathryn Wengel	Independent Director	3.7yrs	US$330.01k	0.0027% $ 553.0k
Kirsten Kliphouse	Independent Director	2.1yrs	US$330.01k	0.0016% $ 318.9k

9.7yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: 0JSYDie Vorstandsmitglieder gelten als erfahren (9.7 Jahre durchschnittliche Amtszeit).

Labcorp Holdings Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

CFO & Executive VP recently sold US$3.4m worth of stock

Insider recently sold US$2.8m worth of stock

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

CFO & Executive VP recently sold US$4.4m worth of stock

Independent Director recently sold US$1.1m worth of stock

Recent updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Upcoming dividend of US$0.72 per share

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold US$3.4m worth of stock

Insider recently sold US$2.8m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023)

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Upcoming dividend of US$0.72 per share

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.35 in 1Q 2023)

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

CFO & Executive VP recently sold US$4.4m worth of stock

Upcoming dividend of US$0.72 per share

Full year 2023 earnings released: EPS: US$4.35 (vs US$14.04 in FY 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.91 in 3Q 2022)

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold US$1.1m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

First quarter 2023 earnings released: EPS: US$2.41 (vs US$5.28 in 1Q 2022)

Insider recently sold US$1.3m worth of stock

Full year 2022 earnings released: EPS: US$14.04 (vs US$24.58 in FY 2021)

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Now 21% undervalued

Upcoming dividend of US$0.72 per share at 1.2% yield

Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023